IDXG INTERPACE BIOSCIENCES, INC.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1054102 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-9.7%
TTM net income YoY355.8%
TTM EPS YoY217.6%
Revenue 3-yr CAGR-12.3%
Net income 3-yr CAGR—
Margins
Gross margin65.6%
Operating margin1.6%
Net margin58.1%
FCF margin7.6%
EBITDA margin3.0%
Returns
ROE179.8%
ROA88.6%
ROIC (approx.)6.2%
Asset turnover1.53x
Leverage & solvency
Liabilities / assets34.1%
Debt / equity0.00x
Current ratio2.06x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.16x
Accruals ratio74.5%
Payout ratio—
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.37M | $9.13M | $9.03M | $9.22M | $8.76M | $9.23M | $11.52M | $12.32M |
| Cost of revenue | $3.19M | $3.48M | $3.13M | $3.18M | $3.32M | $3.96M | $4.14M | $3.40M |
| Gross profit | $7.18M | $5.65M | $5.90M | $6.04M | $5.44M | $5.28M | $7.37M | $8.92M |
| R&D expense | $160,000 | $149,000 | $153,000 | $142,000 | $150,000 | $173,000 | $177,000 | $193,000 |
| SG&A expense | $6.72M | $2.98M | $2.45M | $2.21M | $2.06M | $2.66M | $2.55M | $2.57M |
| Operating income | -$2.40M | $321,000 | $1.12M | $1.58M | $1.15M | -$468,000 | $1.83M | $3.07M |
| Interest expense | — | — | — | — | $30,000 | $49,000 | $78,000 | — |
| Pretax income | -$2.38M | $330,000 | $1.13M | $1.53M | $1.00M | -$533,000 | $1.77M | $2.87M |
| Income tax | -$884,000 | $64,000 | $302,000 | -$21.22M | -$11,000 | $0 | $18,000 | -$8,000 |
| Net income | -$1.61M | $158,000 | $721,000 | $22.66M | $911,000 | -$640,000 | $1.65M | $2.89M |
| EBITDA | -$2.26M | $448,000 | $1.24M | $1.70M | $1.26M | -$367,000 | $1.92M | $3.17M |
| EPS (basic) | -0.28 | 0.01 | 0.03 | — | 1.03 | -0.14 | 0.37 | — |
| EPS (diluted) | -0.28 | 0.01 | 0.03 | — | 0.16 | -0.14 | 0.06 | — |
| Weighted avg. shares (diluted) | 5.71M | 27.71M | 27.71M | — | 5.54M | 4.42M | 27.70M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.93M | $2.69M | $2.65M | $2.50M | $1.42M | $502,000 | $1.20M | $1.46M |
| Receivables | $7.60M | $6.31M | $5.92M | $5.65M | $5.97M | $7.23M | $8.77M | $8.54M |
| Inventory | $1.27M | $1.08M | $961,000 | $1.11M | $1.10M | $973,000 | $1.21M | $1.21M |
| Current assets | $13.29M | $10.97M | $9.96M | $9.90M | $9.13M | $9.50M | $11.65M | $11.77M |
| PP&E, net | $1.45M | $1.62M | $1.31M | $1.42M | $1.54M | $1.37M | $1.28M | $1.36M |
| Total assets | $37.47M | $34.55M | $33.41M | $33.84M | $12.04M | $12.34M | $14.49M | $14.79M |
| Current liabilities | $6.44M | $4.95M | $3.96M | $5.10M | $5.95M | $7.15M | $8.68M | $10.62M |
| Total liabilities | $12.78M | $11.30M | $10.33M | $11.47M | $12.33M | $13.55M | $15.08M | $17.01M |
| Shareholders' equity | $24.69M | $23.24M | $23.08M | $22.36M | -$298,000 | -$1.21M | -$582,000 | -$2.22M |
| Shares outstanding | 5.90M | 27.70M | 27.70M | 885,708 | 4.43M | 4.42M | 4.42M | 4.41M |
| Cash flow statement | ||||||||
| Operating cash flow | $970,000 | $98,000 | $283,000 | $2.14M | $1.94M | $520,000 | $1.24M | $1.18M |
| Capital expenditure | $376,000 | $57,000 | $141,000 | $38,000 | $117,000 | — | — | $129,000 |
| Free cash flow | $594,000 | $41,000 | $142,000 | $2.10M | $1.82M | — | — | $1.05M |
| Investing cash flow | -$369,000 | -$57,000 | -$141,000 | -$38,000 | -$117,000 | — | — | -$129,000 |
| Financing cash flow | — | — | — | -$1.02M | -$900,000 | -$1.01M | -$1.50M | -$1.71M |
| Depreciation & amortization | $141,000 | $127,000 | $118,000 | $118,000 | $111,000 | $101,000 | $95,000 | $95,000 |
| Stock-based compensation | $3.99M | $4,000 | $4,000 | $4,000 | $7,000 | $9,000 | $15,000 | $73,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.